Organ Preservation in Early Rectal Cancer Patients

Rectal Cancer Clinical Trial

Official title:

GI-116: Phase II Study of Organ Preservation in Early Rectal Cancer Patients

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT03548961
• Other study ID #: GI-116
• Secondary ID: 18-1013
• Status: Suspended
• Phase: Phase 2
• Start date: May 11, 2018
• Est. completion date: March 1, 2027

Study information

• Verified date: April 2024
• Source: Fox Chase Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single arm phase II study of neoadjuvant chemotherapy followed by local excision and post-operative chemoradiotherapy in patients with early stage, low rectal adenocarcinoma. After completion of pre-treatment tests/procedures (including pelvic MRI/ERUS; MRI is mandatory at baseline and other imaging is encouraged) and confirmation of eligibility, systemic therapy with FOLFOX will be administered for 12 weeks. 2 to 4 weeks after the chemotherapy, restaging of the primary tumor will be done to evaluate response to therapy (Pelvic MRI and /or sigmoidoscopy). Patients with disease progression or inadequate response to chemotherapy to allow local excision will continue with evaluation and treatment per the current standard of care (chemoradiation followed by TME). These patients will be considered failures for the primary endpoint of the study. Patients who respond to the neoadjuvant chemotherapy will proceed with local excision (open, TEMS or TAMIS), 6-12 weeks after the completion of neoadjuvant chemotherapy, followed by 5-FU based chemoradiotherapy 4-12 weeks after local excision. Patients with positive margins at the time of local excision will also be treated as per standard of care and will be considered as failures. Number of patients who can undergo successful local excision with this approach will define the success of the strategy. After chemoradiation therapy post local excision, patients will be followed closely every 3 months for the first 3 years and then every 2 months for the next 2 years (history/physical, CEA and pelvic MRI). Patients who are deemed failures for the primary end-point will be followed as per standard of care, off-study.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 19
• Est. completion date: March 1, 2027
• Est. primary completion date: March 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria

1. Histologically proven adenocarcinoma of the lower rectum (lower border =6 cm from anal verge as assessed by pelvic MRI).

2. Clinical stage T1N0, T2N0, T3N0; high risk T1 and low risk T3 stage patients are also allowed. Clinical staging should be estimated based on the combination of the following assessments: physical exam by the primary surgeon, CT Chest/Abdomen/Pelvis or PET/CT along with Pelvic MRI and Endoscopic Rectal Ultrasound (ERUS). If a pelvic MRI is performed, it is acceptable to perform CT of the chest/abdomen, omitting CT imaging of the pelvis.

3. No prior therapy for rectal cancer

4. Age > 18 years.

5. ECOG performance status 0 or 1

6. Patients must have normal organ and marrow function as defined below

• Leukocytes > 3,000/mcL

• Absolute neutrophil count > 1,500/mcL

• Platelets > 100,000/mcL

• Total bilirubin < 1.5 times ULN

• AST/ALT (SGOT/SGPT) < 3 times institutional normal limits

• Creatinine < 1.5 times ULN OR

• Creatinine clearance > 60 Ml/min/1.73 m2 for patients with creatinine levels above institutional normal

7. Ability to understand and willingness to sign a written informed consent and HIPAA consent document

Exclusion Criteria:

1. Patients with contraindication to use FOLFOX chemotherapy and pelvic radiation.

2. Low risk T1 tumors that fulfill all of the following - size<4 cm, lack of lymphovascular invasion and well differentiated histology, are excluded

3. High risk T3 tumors that fulfill any of the following - circumferential tumor, extension into mesorectal fascia > 5mm, prediction of positive circumferential resection margin, are also excluded.

4. T4, node positive or advanced rectal adenocarcinoma. Node positivity defined as nodes greater than 1cm in short axis with loss of uniform cortex/fatty hilum

5. Patients receiving other investigational agents

6. Patients who have had chemotherapy (for other malignancies) within 3 years prior to registration

7. Patients with any prior pelvic radiation therapy

8. Prior malignancies requiring systemic therapy within the last 3 years (as prior therapy can increase toxicity of current chemo regimen, those patients should be excluded).

9. History of allergic reactions attributed to compound of similar chemical or biologic composition to the agents used in this study

10. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

11. Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with chemotherapeutic drugs. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.

12. Pregnant or breast feeding.

Related Conditions & MeSH terms

• Rectal Cancer
• Rectal Neoplasms

Intervention

Drug:
• FOLFOX regimen
FOLFOX regimen will be administered for 6 cycles. Each cycle is 14 days followed by restaging, local surgery and concurrent chemo radiation therapy

Locations

Country	Name	City	State
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Fox Chase Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of patients whose tumor can be resected by local excision with negative margins	Patients who undergo neoadjuvant chemotherapy, and are able to achieve a local excision in early stage lower rectal adenocarcinoma with negative margins	3 months
Secondary	Number of patients with improved bowel function in patients treated with organ preserving approach for early stage low rectal cancer before and after therapy	Bowel function will be assessed by Bowel Function Index- Functional Assessment of Chronic Illness Therapy (FACIT) version 4 survey to be completed by patients. The survey measures- Physical well-being, social/family well-being, emotional well-being, functional well-being	3 years
Secondary	Number of patients with improved sexual function treated with organ preserving approach for early stage low rectal cancer before and after therapy	Sexual function in women will be assessed by Female Sexual Function Index (FSFI) 2000 and in men will be assessed by International Index of Erectile Function (IIEF) questionnaire respectively to be completed by patients. The questions ask about the patients' sexual feelings and responses.	3 years
Secondary	Number of patients with improved health-related quality of life treated with organ preserving approach for early stage low rectal cancer before and after therapy	Quality of life will be assessed by Patient Reported Outcome Measurement Information System-10 (PROMIS-10) questionnaire to be completed by patients. This questionnaire will have 10 questions.PROMIS Global-10 allows each of the individual items to be examined separately to provide specific information about perceptions of physical function, pain, fatigue, emotional distress, social health and general perceptions of health.	3 years
Secondary	Overall survival (OS) of patients	OS will be assessed from start of treatment for disease that the patient is still alive	5 years
Secondary	Disease-free survival (DFS) of patients	DFS will be assessed as the length of time that patient survived without any sign of symptoms of that cancer	5 years